Increasing evidence suggests that FUBP1 is overexpressed in a variety of malignancies, including prostate cancer, bladder cancer, liver cancer, colon cancer, breast cancer, non-small-cell lung cancer (NSCLC), glioma, and gastric cancer [19–30]. Here, FUBP1 is linked to non-small cell lung carcinoma.